-
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-09-20 13:36:34ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in
-
ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 TrialDaiichi Sankyo2021-09-20 13:34:15ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced
-
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid CancersDaiichi Sankyo2021-09-20 13:29:26DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers
-
DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-09-16 13:19:50DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric
-
Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO CongressDaiichi Sankyo2021-09-07 10:01:35Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress
-
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-08-09 10:47:51ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus
-
DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-07-08 09:52:59DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-25 10:28:57DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:18:08DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:12:57DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
